X-linked hypophosphatemia (XLH), also known as hereditary type I hypophosphatemia (HPDR I) or familial hypophosphatemia, is an inherited, chronic condition that causes your body to lose phosphate.

Optimal cellular function is dependent on maintenance of a normal serum phosphorus concentration. Serum phosphorus concentration is affected by several determinants, the most important of which is ...

Please provide your email address to receive an email when new articles are posted on . “Anemia is the most common extraintestinal manifestation of IBD, and iron deficiency and inflammation are its ...

The pharmaceutical drug Injectafer (generic name: ferric carboxymaltose), an iron carbohydrate complex used to treat iron deficiency anemia, has been linked to severe hypophosphatemia (HPP) – a ...

Santiago and coauthors conducted a prospective, observational study to analyze the incidence of and risk factors for hypophosphatemia in critically ill children treated with continuous renal ...

Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases ...

X-linked hypophosphatemia (XLH) is the classical bone disorder caused by renal wasting of the phosphate. Formerly called vitamin D-resistant rickets, it is the most frequently observed condition among ...

X-linked hypophosphatemia (XLH) is a genetic disorder affecting the bones, which presents with a wide spectrum of clinical severity, ranging from simple low blood phosphate levels to severe bowlegs.

Nat Clin Pract Nephrol. 2006;2(3):136-148. Hypophosphatemia associated with primary hyperparathyroidism is usually of moderate severity; increased urinary phosphate excretion is balanced by ...

The pharmaceutical drug Injectafer (generic name: ferric carboxymaltose), an iron carbohydrate complex used to treat iron deficiency anemia, has been linked to severe hypophosphatemia (HPP) – a ...